Increased matrix metalloproteinase 2 activity in the human internal mammary artery is associated with ageing, hypertension, diabetes and kidney dysfunction

Journal of Vascular Research

Volumn 45, Issue 4, 2008, Pages 357-362

  Chung, A W ^a   Booth, A D ^a   Rose, C ^a   Thompson, C R ^a   Levin, A ^a   Van Breemen, C ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

Diabetes; Hypertension; Internal mammary artery; Kidney function; Matrix metalloproteinase 2

Indexed keywords

GELATINASE A;

ADULT; AGED; AGING; ARTICLE; CARDIOVASCULAR RISK; CLINICAL ARTICLE; CONTROLLED STUDY; DEMOGRAPHY; DIABETES MELLITUS; ENZYME ACTIVITY; FEMALE; GLOMERULUS FILTRATION RATE; HUMAN; HYPERTENSION; INTERNAL MAMMARY ARTERY; KIDNEY FAILURE; KIDNEY FUNCTION; MALE; PRIORITY JOURNAL; SMOKING; ZYMOGRAPHY;

ADULT; AGED; AGED, 80 AND OVER; AGING; DIABETES MELLITUS, TYPE 2; GLOMERULAR FILTRATION RATE; HUMANS; HYPERTENSION; KIDNEY DISEASES; MAMMARY ARTERIES; MATRIX METALLOPROTEINASE 2; MIDDLE AGED;

EID: 44849099266     PISSN: 10181172     EISSN: None     Source Type: Journal    
DOI: 10.1159/000119755     Document Type: Article

References (24)

1. Galis ZS, Khatri JJ: Matrix metalloproteinases in vascular remodeling and atherogenesis: the good, the bad, and the ugly. Circ Res 2002;90:251-262.
2. Newby AC, Southgate KM, Davies M: Extracellular matrix degrading metalloproteinases in the pathogenesis of arteriosclerosis. Basic Res Cardiol 1994;89(suppl 1):59-70.
3. Chung AW, Rauniyar P, Luo H, Hsiang YN, van Breemen C, Okon EB: Pressure distention compared with pharmacologic relaxation in vein grafting upregulates matrix metalloproteinase-2 and -9. J Vasc Surg 2005;42:747-756.
4. Southgate KM, Fisher M, Banning AP, Thurston VJ, Baker AH, Fabunmi RP, Groves PH, Davies M, Newby AC: Upregulation of basement membrane-degrading metalloproteinase secretion after balloon injury of pig carotid arteries. Circ Res 1996;79:1177-1187.
5. Southgate KM, Mehta D, Izzat MB, Newby AC, Angelini GD: Increased secretion of basement membrane-degrading metalloproteinases in pig saphenous vein into carotid artery interposition grafts. Arterioscler Thromb Vasc Biol 1999;19:1640-1649.
6. Hojo Y, Ikeda U, Katsuki T, Mizuno O, Fujikawa H, Shimada K: Matrix metalloproteinase expression in the coronary circulation induced by coronary angioplasty. Atherosclerosis 2002;161:185-192.
7. Rajagopalan S, Meng XP, Ramasamy S, Harrison DG, Galis ZS: Reactive oxygen species produced by macrophage-derived foam cells regulate the activity of vascular matrix metalloproteinases in vitro. Implications for atherosclerotic plaque stability. J Clin Invest 1996;98:2572-2579.
8. Okon EB, Chung AW, Rauniyar P, Padilla E, Tejerina T, McManus BM, Luo H, van Breemen C: Compromised arterial function in human type 2 diabetic patients. Diabetes 2005;54:2415-2423.
9. Chung AW, Hsiang YN, Matzke LA, McManus BM, van Breemen C, Okon EB: Reduced expression of vascular endothelial growth factor paralleled with the increased angiostatin expression resulting from the upregulated activities of matrix metalloproteinase-2 and -9 in human type 2 diabetic arterial vasculature. Circ Res 2006;99:140-148.
10. Li Z, Froehlich J, Galis ZS, Lakatta EG: Increased expression of matrix metalloproteinase-2 in the thickened intima of aged rats. Hypertension 2000;35:55-60.
11. Wang M, Takagi G, Asai K, Resuello RG, Natividad FF, Vatner DE, Vatner SF, Lakata EG: Aging increases aortic MMP-2 activity and angiotensin II in nonhuman primates. Hypertension 2003;41:1308-1316.
12. Wright JL, Tai H, Wang R, Wang X, Churg A: Cigarette smoke upregulates pulmonary vascular matrix metalloproteinases via TNF-alpha signaling. Am J Physiol Lung Cell Mol Physiol 2007;292:L125-L133.
13. Cheng S, Pollock AS, Mahimkar R, Olson JL, Lovett DH: Matrix metalloproteinase 2 and basement membrane integrity: a unifying mechanism for progressive renal injury. FASEB J 2006;20:1898-1900.
14. Ergul A, Portik-Dobos V, Hutchinson J, Franco J, Anstadt MP: Downregulation of vascular matrix metalloproteinase inducer and activator proteins in hypertensive patients. Am J Hypertens 2004;17:775-782.
15. Newby AC: Matrix metalloproteinases regulate migration, proliferation, and death of vascular smooth muscle cells by degrading matrix and non-matrix substrates. Cardiovasc Res 2006;69:614-624.
16. Johnson C, Galis ZS: Matrix metalloproteinase-2 and -9 differentially regulate smooth muscle cell migration and cell-mediated collagen organization. Arterioscler Thromb Vasc Biol 2004;24:54-60.
17. Kuzuya M, Kanda S, Sasaki T, Tamaya-Mori N, Cheng XW, Itoh T, Itohara S, Iguchi A: Deficiency of gelatinase A suppresses smooth muscle cell invasion and development of experimental intimal hyperplasia. Circulation 2003;108:1375-1381.
18. Sanders JS, van Goor H, Hanemaaijer R, Kallenberg CG, Stegeman CA: Renal expression of matrix metalloproteinases in human ANCA-associated glomerulonephritis. Nephrol Dial Transplant 2004;19:1412-1419.
19. McNulty M, Spiers P, McGovern E, Feely J: Aging is associated with increased matrix metalloproteinase-2 activity in the human aorta. Am J Hypertens 2005;18:504-509.
20. Bauvois B, Mothu N, Nguyen J, Nguyen-Khoa T, Noel LH, Jungers P: Specific changes in plasma concentrations of matrix metalloproteinase-2 and -9, TIMP-1 and TGF-beta1 in patients with distinct types of primary glomerulonephritis. Nephrol Dial Transplant 2007;22:1115-1122.
21. Chang HR, Yang SF, Li ML, Lin CC, Hsieh YS, Lian JD: Relationships between circulating matrix metalloproteinase-2 and -9 and renal function in patients with chronic kidney disease. Clin Chim Acta 2006;366:243-248.
22. Liu BC, Zhang L, Lv LL, Wang YL, Liu DG, Zhang XL: Application of antibody array technology in the analysis of urinary cytokine profiles in patients with chronic kidney disease. Am J Nephrol 2006;26:483-490.
23. Hirahara I, Inoue M, Okuda K, Ando Y, Muto S, Kusano E: The potential of matrix metalloproteinase-2 as a marker of peritoneal injury, increased solute transport, or progression to encapsulating peritoneal sclerosis during peritoneal dialysis - a multicentre study in Japan. Nephrol Dial Transplant 2007;22:560-567.
24. Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY: Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 2004;351:1296-1305.